search
Back to results

Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 (eBAM_CoV)

Primary Purpose

SARS-CoV-2 Infection, COVID-19, Coronavirus

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
eBAM Cov Testing
Sponsored by
Centre Hospitalier Universitaire de Nīmes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for SARS-CoV-2 Infection focused on measuring Diagnostic Test Kits

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Adult male or female patients over 18 years of age (≥) Suspected of being infected with COVID-19 (symptomatic or contact case) and consulting for RT-PCR screening. Exclusion Criteria: Inability to understand the procedures to use the device Patient participating in an another interventional study Patient in exclusion period determined by another study Patient under court protection or guardianship Patient/trusted person/legal representative/family member for whom it is impossible to give informed information. Pregnant, parturient or breast-feeding patient

Sites / Locations

  • Laboratoire Alphabio, Hôpital Européen Marseille
  • CHU de NIMES

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients likely to be affected by COVID-19

Arm Description

The study population consists of adult people who are likely to be affected by COVID-19 (symptomatic or close contacts) consulting for RT-PCR screening.

Outcomes

Primary Outcome Measures

Concordance between eBAM-Cov test and RT -PCR test to detect SARS-CoV -2 infection
Evaluate the performance of the eBAM-CoV test by measuring the concordance between the eBAM-CoV method and the reference RT-PCR method (known as the "gold standard") in detecting SARS-CoV-2 in subjects likely to be infected with COVID-19 (symptomatic or closed contacts).

Secondary Outcome Measures

diagnostic performance of the eBAM-CoV test
Preliminarily assess the diagnostic performance of the eBAM-CoV test by measuring the sensitivity/specificity between the eBAM-CoV method and the reference RT-PCR method (known as the "gold standard") for detecting SARS-CoV-2 in subjects likely to be infected with COVID-19 (symptomatic or closed contact).
concentration of SARS-CoV-2 viral proteins
Correlation between the concentration of SARS-CoV-2 viral proteins assessed by the eBAM-CoV test (eBAM-Unit) and the mean number of copies of mRNA encoding a protein fraction of SARS-CoV-2 viral proteins assessed using the RT-PCR technique
Early detection of SARS-CoV-2 using eBAM-CoV test versus RT-PCR
Number of patients detected as positive by eBAM-CoV and negative by RT-PCR at Day 0 whose RT-PCR test becomes positive at Day 4
Concordance between eBAM-CoV test and antigenic test
Concordance between the eBAM-CoV method and the antigenic test in patients likely to be infected with COVID-19 and volunteering for a second nasopharyngeal swab

Full Information

First Posted
October 18, 2023
Last Updated
October 23, 2023
Sponsor
Centre Hospitalier Universitaire de Nīmes
Collaborators
University of Nimes, brains' laboratory sas, FRANCE
search

1. Study Identification

Unique Protocol Identification Number
NCT06099795
Brief Title
Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2
Acronym
eBAM_CoV
Official Title
Evaluation of Concordance Between an Innovative Test on Exhaled Air (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 in Symptomatic Patients or Closed Contacts
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 2024 (Anticipated)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
June 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nīmes
Collaborators
University of Nimes, brains' laboratory sas, FRANCE

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabs to detect the SARS-CoV-2 virus, responsible for the disease. However, this technique has several limitations, including the variable quality of swabs, its invasive nature, and arbitrariness in the choice of the number of cycles. Furthermore, it does not allow for the detection of viral proteins. To overcome these limitations, researchers developed the eBAM-CoV test, patented for the detection of viral proteins in the exhaled air of COVID-19 patients. This portable device provides an immediate assessment of the "viral load" with both quantitative and qualitative results, showing promise for early virus detection. The researchers hypothesize that the eBAM-CoV test is likely to exhibit a satisfactory concordance with the reference RT-PCR test in the detection of COVID-19, especially among symptomatic patients or closed contacts.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
SARS-CoV-2 Infection, COVID-19, Coronavirus
Keywords
Diagnostic Test Kits

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patients likely to be affected by COVID-19
Arm Type
Experimental
Arm Description
The study population consists of adult people who are likely to be affected by COVID-19 (symptomatic or close contacts) consulting for RT-PCR screening.
Intervention Type
Device
Intervention Name(s)
eBAM Cov Testing
Intervention Description
Evaluation of presence/absence of infection with SARS-CoV-2 assessed by eBAM-CoV on air exhaled by the patient compared with the presence/absence of infection based on RT-PCR testing of nasopharyngeal swabs
Primary Outcome Measure Information:
Title
Concordance between eBAM-Cov test and RT -PCR test to detect SARS-CoV -2 infection
Description
Evaluate the performance of the eBAM-CoV test by measuring the concordance between the eBAM-CoV method and the reference RT-PCR method (known as the "gold standard") in detecting SARS-CoV-2 in subjects likely to be infected with COVID-19 (symptomatic or closed contacts).
Time Frame
Day 0
Secondary Outcome Measure Information:
Title
diagnostic performance of the eBAM-CoV test
Description
Preliminarily assess the diagnostic performance of the eBAM-CoV test by measuring the sensitivity/specificity between the eBAM-CoV method and the reference RT-PCR method (known as the "gold standard") for detecting SARS-CoV-2 in subjects likely to be infected with COVID-19 (symptomatic or closed contact).
Time Frame
Day 0
Title
concentration of SARS-CoV-2 viral proteins
Description
Correlation between the concentration of SARS-CoV-2 viral proteins assessed by the eBAM-CoV test (eBAM-Unit) and the mean number of copies of mRNA encoding a protein fraction of SARS-CoV-2 viral proteins assessed using the RT-PCR technique
Time Frame
Day 0
Title
Early detection of SARS-CoV-2 using eBAM-CoV test versus RT-PCR
Description
Number of patients detected as positive by eBAM-CoV and negative by RT-PCR at Day 0 whose RT-PCR test becomes positive at Day 4
Time Frame
Day 4
Title
Concordance between eBAM-CoV test and antigenic test
Description
Concordance between the eBAM-CoV method and the antigenic test in patients likely to be infected with COVID-19 and volunteering for a second nasopharyngeal swab
Time Frame
Day 0

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult male or female patients over 18 years of age (≥) Suspected of being infected with COVID-19 (symptomatic or contact case) and consulting for RT-PCR screening. Exclusion Criteria: Inability to understand the procedures to use the device Patient participating in an another interventional study Patient in exclusion period determined by another study Patient under court protection or guardianship Patient/trusted person/legal representative/family member for whom it is impossible to give informed information. Pregnant, parturient or breast-feeding patient
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Valérie COMPAN, PhD
Phone
+33664915140
Email
vcompan@brains4d.com
Facility Information:
Facility Name
Laboratoire Alphabio, Hôpital Européen Marseille
City
Marseille
ZIP/Postal Code
13003
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe HALFON, MD, PhD
Phone
+33413428120
Email
philippe.halfon@biogroup.fr
First Name & Middle Initial & Last Name & Degree
Philippe HALFON, MD, PhD
Facility Name
CHU de NIMES
City
Nîmes
ZIP/Postal Code
30029
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul LOUBET, MD, PhD
Phone
+33466684149
Email
paul.loubet@chu-nimes.fr
First Name & Middle Initial & Last Name & Degree
Paul LOUBET, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2

We'll reach out to this number within 24 hrs